Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer.

Wikman H, Nymark P, Väyrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M, Anttila S.

Genes Chromosomes Cancer. 2005 Feb;42(2):193-9.

PMID:
15543620
2.

Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.

Miller CT, Aggarwal S, Lin TK, Dagenais SL, Contreras JI, Orringer MB, Glover TW, Beer DG, Lin L.

Cancer Res. 2003 Jul 15;63(14):4136-43.

3.

Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification.

Heidenblad M, Jonson T, Mahlamäki EH, Gorunova L, Karhu R, Johansson B, Höglund M.

Genes Chromosomes Cancer. 2002 Jun;34(2):211-23.

PMID:
11979555
4.

Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma.

Yotov WV, Hamel H, Rivard GE, Champagne MA, Russo PA, Leclerc JM, Bernstein ML, Levy E.

Genes Chromosomes Cancer. 1999 Sep;26(1):62-9.

PMID:
10441007
5.

Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.

Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP.

Cancer Res. 1996 Nov 15;56(22):5141-5.

6.

Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer.

Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G.

Oncogene. 2002 Apr 11;21(16):2476-83.

7.

Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H.

Am J Pathol. 2003 Sep;163(3):985-92.

8.

Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.

Schmidt BA, Rose A, Steinhoff C, Strohmeyer T, Hartmann M, Ackermann R.

Cancer Res. 2001 May 15;61(10):4214-21.

9.

Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene.

Honda S, Tanaka-Kosugi C, Yamada S, Sano T, Matsumoto T, Itakura M, Yoshimoto K.

Endocr J. 2003 Jun;50(3):309-18.

10.

Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.

Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT.

Cancer Res. 1993 Nov 15;53(22):5535-41.

11.

Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.

Ruano Y, Mollejo M, Ribalta T, Fiaño C, Camacho FI, Gómez E, de Lope AR, Hernández-Moneo JL, Martínez P, Meléndez B.

Mol Cancer. 2006 Sep 26;5:39.

12.

The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas.

Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG.

Cancer Res. 2002 Sep 15;62(18):5273-9.

13.

Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.

Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M, Okayasu I.

J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):505-12.

PMID:
10480344
14.

Detection of gene amplification by genomic hybridization to cDNA microarrays.

Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent JM, Meltzer PS.

Cancer Res. 2000 Feb 15;60(4):799-802.

15.

The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.

Louis-Brennetot C, Coindre JM, Ferreira C, Pérot G, Terrier P, Aurias A.

Genes Chromosomes Cancer. 2011 Nov;50(11):896-907. doi: 10.1002/gcc.20909. Epub 2011 Aug 24.

PMID:
21910158
16.

Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations.

Rozeman LB, Szuhai K, Schrage YM, Rosenberg C, Tanke HJ, Taminiau AH, Cleton-Jansen AM, Bovée JV, Hogendoorn PC.

Cancer. 2006 Jul 15;107(2):380-8.

17.

A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma.

Fischer U, Keller A, Leidinger P, Deutscher S, Heisel S, Urbschat S, Lenhof HP, Meese E.

Mol Cancer Res. 2008 Apr;6(4):576-84. doi: 10.1158/1541-7786.MCR-07-0283.

18.

Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.

Wessendorf S, Schwaenen C, Kohlhammer H, Kienle D, Wrobel G, Barth TF, Nessling M, Möller P, Döhner H, Lichter P, Bentz M.

Oncogene. 2003 Mar 6;22(9):1425-9.

PMID:
12618769
19.

Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.

Burns KL, Ueki K, Jhung SL, Koh J, Louis DN.

J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30.

PMID:
9600204
20.

Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.

Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H.

BMC Cancer. 2010 May 5;10:181. doi: 10.1186/1471-2407-10-181.

Supplemental Content

Support Center